In GSE95024, we found that after knockdown of PCBP2, 359 genes were significantly downregulated and 332 genes were significantly upregulated (Figure 6A), 17 of which were significantly enriched in pathways related to the role of proteoglycans in cancer (Figure 6B), including 7 downregulated genes: TIMP3, PAK1, HPSE2, HSPB2, PRKACB, WNT8B, and PLAUR, and 10 upregulated genes: CAV1, FRS2, CCND1, CAV2, AKT3, SHH, FGF2, PIK3R3, WNT7A, and THBS1. The gene discussed is PCBP2; the disease is cancer.